Das Studienregister der UME

allo-APZ2-CVU-III

A Pivotal, Randomized, Placebo-controlled, Double-blind, Multicenter, International Phase III Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Non-Healing Chronic Venous Ulcers (CVU)

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

NCT-Nummer: NCT06489028

ARCHITECT

Non-Interventionelle ADOREG Registerstudie zur Charakterisierung einer Kombination aus Immuntherapie und Elektrochemotherapie beim malignen Melanom

Berufsordnung (BO) / Nicht-interventionell

BI 1368-0140

A multi-centre, randomised, placebo-controlled, double-blind, parralelgroup trial to evaluate safety and efficacy of spesolimab (BI 655130) i.v. in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

CDX0159-13

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)

Clinical Trial Regulation (CTR) / Interventionell

NCT-Nummer: NCT06455202

D346BC00001 LAVENDER

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Animalarial Therapy

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

EudraCT-Nummer: 2021-003698-70

NCT-Nummer: NCT06015737

DICIT

Efficacy of diclofenac added to ongoing PD-1 inhibitor therapy in metastatic melanoma patients

Arzneimittelgesetz (AMG) / Phase 2, Interventionell

IMA203-301

A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

IMA402-101

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA402, a Bispecific T Cell Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Arzneimittelgesetz (AMG) / Phase 1, Interventionell, Multizentrisch

IMC-F106C-301

A Phase 3 Randomized, Controlled Study of IMC-F 106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

NCT-Nummer: NCT06112314

IMCgp100-203 

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

Arzneimittelgesetz (AMG) / Phase 2, Interventionell, Multizentrisch

EudraCT-Nummer: 2022-502732-39-00

NCT-Nummer: NCT05549297

SKABUP

Multizentrische, prospektive, randomisierte, doppelblinde Phase III-Studie zum Vergleich der Wirksamkeit und Sicherheit der Therapie der Skabies mit zwei unterschiedlich konzentrierten Permethrin-Cremes

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch

23-BI-1607-02

AN OPEN-LABEL, MULTICENTRE PHASE 1B/2A CLINICAL TRIAL OF BI-1607, AN FC-ENGINEERED MONOCLONAL ANTIBODY TO FCyRIIB (CD32B), IN COMBINATION WITH IPILIMUMAB AND PEMBROLIZUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA

Clinical Trial Regulation (CTR) / Interventionell, Multizentrisch